Kiyatec
Greenville, US · Founded 2010 · Delaware corporation · 14 employees on LinkedIn · 5 known investors
Find your way into Kiyatec
271 people in our graph share verified history with the Kiyatec team — schools, employers, funds. One of them is your warm intro.
Daisuke Minamideunlockedknows David E Orr · together at Purdue University Daniels School of Business
×2knows the team · via Rose-Hulman Institute of Technology
×4knows the team · via Siena University
knows the team · via T2 Biosystems
knows the team · via American Greetings
×3knows the team · via University of Maryland Global Campus
KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
Founders & leadership
Kiyatec was founded in 2010 by Matthew Gevaert.
MG
Matthew GevaertFounder
EP
Eric PerreaultinChief Executive OfficerEric Perreault brings over 25 years of experience in medical sales and marketing leadership, including expertise in launching novel biomarkers and technologies across healthcare segments and managing fundraising and board relations.
MR
Melissa RaynerinVice President Operations2023–2025Melissa Rayner holds a Bachelor of Science in Biology from North Carolina Central University and a Master of Science in Biotechnology with a focus on Regulatory Affairs from University of Maryland Global Campus. She brings experience in clinical laboratory accreditation (CAP, CLIA, and NY state), clinical trials oversight, and market access strategy for laboratory diagnostics.
SI
Scott IsackseninVice President of Sales2024–2026Scott Isacksen is an Executive Officer at Kiyatec, which develops a tumor-specific testing platform for precision oncology. He previously held senior commercial leadership roles at Cubist, where he led sales teams that generated $400 million in revenue, and at other pharmaceutical and medical device companies where he launched products and built sales organizations across multiple therapeutic areas.
DE
David E OrrinCo-founder2005–2015He brings experience in product development, operational management, and commercialization across life science and medical device companies.
Board
CB
Christopher BrothertonBoard director
JR
RS
Robert SilvermanBoard director
BN
Bruce NashBoard director
ME
Martin EttlemyerBoard director
GZ
Gregory ZaicBoard director
HL
H. Lee Higdon IIIBoard director
Investors · 5
Atlanta Technology AngelsAtlanta · $200K – $2M
Seae VenturesMiamivia Jason Robart · board
VentureSouthreportedGreenville
Also in the syndicate · 2
BrukerleadLabCorp
Reported raises · per SEC filings
Form D private placements$27M disclosed across 5 of 7 rounds · 2014–2024
▶$250KraisedNov 2024 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric PerreaultExecutive Officer, Director
- Christopher BrothertonDirector
- Matthew GevaertDirector
- Melissa RaynerExecutive Officer
- Scott IsacksenExecutive Officer
- Jason RobartDirector
- Robert SilvermanDirector
- Bruce NashDirector
- Offering amount
- $5.4M
- Amount sold
- $250K
- Minimum investment
- $50K
- Sales commissions
- $206.5K
- Proceeds to insiders
- $830K
- Placement agents
- Nicholas McFarland
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.1MraisedDec 2022 · 23 investors · BiotechnologyRule 506(b)
▶$18.1MraisedDec 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew R. GevaertExecutive Officer, Director
- Bruce NashDirector
- Jason RobartDirector
- Robert SilvermanDirector
- Christopher BrothertonDirector
- Offering amount
- $24.6M
- Amount sold
- $18.1M
- Sales commissions
- $611K
- Placement agents
- WILLIAM BLAIR & COMPANY L.L.C.
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.3MraisedMar 2019 · 15 investors · BiotechnologyRule 506(b)
▶$5.3MraisedMar 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christine Dixon ThiesingDirector
- Gregory ZaicDirector
- Christopher BrothertonDirector
- Matthew R. GevaertExecutive Officer, Director
- Offering amount
- $14.3M
- Amount sold
- $5.3M
- Minimum investment
- $6.3K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedNov 2017 · BiotechnologyRule 506(b)
▶$2MofferedNov 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. SilvermanDirector
- Christine Dixon ThiesingDirector
- Matthew R. GevaertExecutive Officer, Director
- Christopher BrothertonDirector
- Gregory ZaicDirector
- Offering amount
- $2M
- Proceeds to insiders
- $45K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedOct 2016 · 24 investors · BiotechnologyRule 506(b)
▶$3.1MraisedOct 2016 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew GevaertExecutive Officer, Director
- Christopher BrothertonDirector
- Martin EttlemyerDirector
- Gregory ZaicDirector
- Bob SilvermanDirector
- Offering amount
- $5.2M
- Amount sold
- $3.1M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$180KraisedDec 2014 · 3 investors · BiotechnologyRule 506(b)
▶$180KraisedDec 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory ZaicDirector
- David E OrrExecutive Officer
- Bob SilvermanDirector
- Matthew GevaertExecutive Officer, Director
- H. Lee Higdon IIIDirector
- Christopher BrothertonDirector
- Offering amount
- $500K
- Amount sold
- $180K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500.5KofferedApr 2014 · BiotechnologyRule 506(b)
▶$500.5KofferedApr 2014 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory ZaicDirector
- Bob SilvermanDirector
- Christopher BrothertonDirector
- Matthew GevaertExecutive Officer, Director
- H. Lee Higdon IIIDirector
- David E OrrExecutive Officer
- Offering amount
- $500.5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapDialectic Therapeutics10 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Newswise8 shared keywordsNewswise is a news distribution platform and press release service that connects journalists, public relations professionals, and the public with research news and expert sources across medical, science, life, and business sectors.
Companies competing with Kiyatec for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $254.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $294.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Kiyatec do?
- KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
- Who founded Kiyatec?
- Kiyatec was founded by Matthew Gevaert in 2010.
- Who are Kiyatec's investors?
- Kiyatec's investors include Atlanta Technology Angels, Seae Ventures, VentureSouth.
- How much funding has Kiyatec raised?
- Kiyatec has disclosed $27M raised across 5 of its 7 known rounds.
- Where is Kiyatec headquartered?
- Kiyatec is headquartered in Greenville, US.